ZEC DAT pivots to cancer drug after $37.8M loss

ahboyashreads (@ahboyashreads), Aug 13, 2026, 10:29 UTC

ZEC DAT pivots to cancer drug after $37.8M loss Cypherpunk Technologies, the Winklevoss-backed Zcash DAT, reported $37.8m net loss for H1 2026 and is pivoting focus to its cancer drug candidate amid a planned FDA trial Source

The excerpt is quoted from a public Telegram channel, which owns its text.

Read the original post on Telegram

More posts from ahboyashreads · All channels